FR2847253B1 - Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant - Google Patents

Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant

Info

Publication number
FR2847253B1
FR2847253B1 FR0214443A FR0214443A FR2847253B1 FR 2847253 B1 FR2847253 B1 FR 2847253B1 FR 0214443 A FR0214443 A FR 0214443A FR 0214443 A FR0214443 A FR 0214443A FR 2847253 B1 FR2847253 B1 FR 2847253B1
Authority
FR
France
Prior art keywords
pyridazinones
medicaments
pharmaceutical compositions
novel derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0214443A
Other languages
English (en)
Other versions
FR2847253A1 (fr
Inventor
Dominique Lesuisse
Franck Halley
Bernard Baudoin
Thomas Rooney
Swen Hoelder
Thorsten Naumann
Gilles Tiraboschi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0214443A priority Critical patent/FR2847253B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to PCT/EP2003/012950 priority patent/WO2004046117A1/fr
Priority to TW092132354A priority patent/TW200418478A/zh
Priority to CA002518917A priority patent/CA2518917A1/fr
Priority to MXPA05005270A priority patent/MXPA05005270A/es
Priority to KR1020057009083A priority patent/KR20050083918A/ko
Priority to AT03811383T priority patent/ATE369356T1/de
Priority to AU2003296586A priority patent/AU2003296586A1/en
Priority to BR0316720-8A priority patent/BR0316720A/pt
Priority to CNA2003801050578A priority patent/CN1741999A/zh
Priority to DE60315516T priority patent/DE60315516T2/de
Priority to US10/715,556 priority patent/US7462613B2/en
Priority to CA002506022A priority patent/CA2506022A1/fr
Priority to EP03811383A priority patent/EP1611121B1/fr
Priority to US10/715,358 priority patent/US7309701B2/en
Priority to PL03376129A priority patent/PL376129A1/xx
Priority to EP03775372A priority patent/EP1581505B1/fr
Priority to AU2003283414A priority patent/AU2003283414A1/en
Priority to TW092132459A priority patent/TW200503727A/zh
Priority to PCT/EP2003/012949 priority patent/WO2004046130A1/fr
Priority to ARP030104278A priority patent/AR042202A1/es
Priority to RU2005119151/04A priority patent/RU2005119151A/ru
Priority to ARP030104280A priority patent/AR042089A1/es
Priority to JP2004552660A priority patent/JP2006509748A/ja
Priority to AT03775372T priority patent/ATE368651T1/de
Priority to DE60315354T priority patent/DE60315354T2/de
Publication of FR2847253A1 publication Critical patent/FR2847253A1/fr
Priority to MA28287A priority patent/MA27814A1/fr
Priority to CO05048069A priority patent/CO5700722A2/es
Priority to NO20052887A priority patent/NO20052887L/no
Application granted granted Critical
Publication of FR2847253B1 publication Critical patent/FR2847253B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR0214443A 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant Expired - Fee Related FR2847253B1 (fr)

Priority Applications (29)

Application Number Priority Date Filing Date Title
FR0214443A FR2847253B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
TW092132459A TW200503727A (en) 2002-11-19 2003-11-19 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
CA002518917A CA2518917A1 (fr) 2002-11-19 2003-11-19 Derives de pyridazinone comme inhibiteurs de cdk2
AU2003283414A AU2003283414A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as gsk-3beta inhibitors
KR1020057009083A KR20050083918A (ko) 2002-11-19 2003-11-19 Ｇｓｋ-3베타 억제제로서의 피리다지논 유도체
AT03811383T ATE369356T1 (de) 2002-11-19 2003-11-19 Pyridazinon-derivate als cdk2-hemmer
AU2003296586A AU2003296586A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as cdk2-inhibitors
TW092132354A TW200418478A (en) 2002-11-19 2003-11-19 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
CNA2003801050578A CN1741999A (zh) 2002-11-19 2003-11-19 用作GSK－3β抑制剂的哒嗪酮衍生物
DE60315516T DE60315516T2 (de) 2002-11-19 2003-11-19 Pyridazinon-derivate als cdk2-hemmer
US10/715,556 US7462613B2 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
CA002506022A CA2506022A1 (fr) 2002-11-19 2003-11-19 Derives de pyridazinones en tant qu'inhibiteurs de gsk-3beta
EP03811383A EP1611121B1 (fr) 2002-11-19 2003-11-19 Derives de pyridazinone comme inhibiteurs de cdk2
PCT/EP2003/012949 WO2004046130A1 (fr) 2002-11-19 2003-11-19 Derives de pyridazinone comme inhibiteurs de cdk2
PCT/EP2003/012950 WO2004046117A1 (fr) 2002-11-19 2003-11-19 Derives de pyridazinones en tant qu'inhibiteurs de gsk-3beta
EP03775372A EP1581505B1 (fr) 2002-11-19 2003-11-19 Derives de pyridazinones en tant qu'inhibiteurs de gsk-3beta
MXPA05005270A MXPA05005270A (es) 2002-11-19 2003-11-19 Nuevos derivados de piridazinona como productos farmaceuticos y composiciones farmaceuticas que los contienen.
BR0316720-8A BR0316720A (pt) 2002-11-19 2003-11-19 Derivados de piridazinona como inibidores de gsk-3beta
US10/715,358 US7309701B2 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
ARP030104278A AR042202A1 (es) 2002-11-19 2003-11-19 Derivados de piridazinona como medicamentos y composiciones farmaceuticas que los contienen
RU2005119151/04A RU2005119151A (ru) 2002-11-19 2003-11-19 Производные пиридазинона в качестве gsk-3бета-ингибиторов
ARP030104280A AR042089A1 (es) 2002-11-19 2003-11-19 Derivados de piridazinona como medicamentos, metodos para su preparacion y composiciones farmaceuticas que los contienen
JP2004552660A JP2006509748A (ja) 2002-11-19 2003-11-19 Ｇｓｋ−３ベータ阻害剤としてのピリダジノン誘導体
AT03775372T ATE368651T1 (de) 2002-11-19 2003-11-19 Pyridazinon-derivate als gsk-3beta-hemmer
DE60315354T DE60315354T2 (de) 2002-11-19 2003-11-19 Pyridazinon-derivate als gsk-3beta-hemmer
PL03376129A PL376129A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as gsk-3beta inhibitors
MA28287A MA27814A1 (fr) 2002-11-19 2005-05-17 Derives de pyridazinones en tant qu'inhibiteurs de gsk-3beta
CO05048069A CO5700722A2 (es) 2002-11-19 2005-05-18 Nuevos derivados de piridazinona como productos farmaceutico y composiciones farmaceuticas que los contienen
NO20052887A NO20052887L (no) 2002-11-19 2005-06-14 Pyridazinonderivater som GSK-3Beta inhibitorer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214443A FR2847253B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant

Publications (2)

Publication Number Publication Date
FR2847253A1 FR2847253A1 (fr) 2004-05-21
FR2847253B1 true FR2847253B1 (fr) 2007-05-18

Family

ID=32187711

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0214443A Expired - Fee Related FR2847253B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant

Country Status (19)

Country Link
EP (2) EP1581505B1 (fr)
JP (1) JP2006509748A (fr)
KR (1) KR20050083918A (fr)
CN (1) CN1741999A (fr)
AR (2) AR042202A1 (fr)
AT (2) ATE368651T1 (fr)
AU (2) AU2003283414A1 (fr)
BR (1) BR0316720A (fr)
CA (2) CA2506022A1 (fr)
CO (1) CO5700722A2 (fr)
DE (2) DE60315354T2 (fr)
FR (1) FR2847253B1 (fr)
MA (1) MA27814A1 (fr)
MX (1) MXPA05005270A (fr)
NO (1) NO20052887L (fr)
PL (1) PL376129A1 (fr)
RU (1) RU2005119151A (fr)
TW (2) TW200418478A (fr)
WO (2) WO2004046130A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264014A1 (fr) 2001-08-31 2010-12-22 Université Louis Pasteur Pyridazines substitués comme anti-inflammatoirs et inhibiteurs de la protéine kinase
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE102004010194A1 (de) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1598348A1 (fr) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Dérivés de pyridazinone comme inhibiteurs de CDK2
EP1604988A1 (fr) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Dérivés de pyridazinone, méthodes de leur préparation et leur utilisation comme pharmaceutiques
JP5094398B2 (ja) 2004-09-20 2012-12-12 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
CA2580857A1 (fr) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
EP1807085B1 (fr) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
BRPI0515489A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
ES2543813T3 (es) 2004-11-02 2015-08-24 Northwestern University Compuestos de piridazina para el tratamiento de enfermedades inflamatorias
EP1812007B1 (fr) 2004-11-02 2011-09-07 Northwestern University Composes pyridazine et methodes
WO2007130075A1 (fr) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
EP2377530A3 (fr) 2005-10-21 2012-06-20 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007127475A2 (fr) * 2006-04-28 2007-11-08 Northwestern University Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur
CA2650625A1 (fr) 2006-04-28 2007-11-08 Northwestern University Formulations contenant un compose de pyridazine
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
WO2008017381A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2012203023C1 (en) * 2009-03-02 2013-11-07 Novartis Ag N-(hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as Wnt signaling modulators
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
GB201201100D0 (en) * 2012-01-20 2012-03-07 Medical Res Council Polypeptides and methods
CA2927567C (fr) 2013-10-18 2022-04-26 Celgene Quanticel Research, Inc. Inhibiteurs de bromodomaine
KR102319882B1 (ko) * 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
PE20190509A1 (es) * 2016-05-25 2019-04-10 Bayer Pharma AG 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
CA3082856A1 (fr) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-2,3-dihydropyridazine-4-carboxamides substitues par du soufre
CN111533697B (zh) * 2020-05-07 2023-03-31 成都大学 4-氨基哒嗪酮类化合物及其制备方法
CN111533735A (zh) * 2020-05-08 2020-08-14 张建蒙 氧代二氢哒嗪噻唑类衍生物及其在抗肿瘤药物中的应用
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (fr) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
WO1999034018A1 (fr) * 1997-12-24 1999-07-08 The Regents Of The University Of California Techniques permettant d'utiliser des banques chimiques pour rechercher de nouveaux inhibiteurs des kinases
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
HU228961B1 (en) * 2000-09-18 2013-07-29 Eisai R & D Man Co Triazinones and their use as active ingredients of pharmaceutical compositions
KR100947185B1 (ko) * 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
ATE368651T1 (de) 2007-08-15
AR042202A1 (es) 2005-06-15
DE60315516D1 (de) 2007-09-20
EP1611121A1 (fr) 2006-01-04
ATE369356T1 (de) 2007-08-15
EP1581505A1 (fr) 2005-10-05
DE60315516T2 (de) 2008-04-17
PL376129A1 (en) 2005-12-12
AU2003283414A1 (en) 2004-06-15
EP1581505B1 (fr) 2007-08-01
MA27814A1 (fr) 2006-04-03
WO2004046117A1 (fr) 2004-06-03
CA2506022A1 (fr) 2004-06-03
RU2005119151A (ru) 2006-01-20
TW200503727A (en) 2005-02-01
AR042089A1 (es) 2005-06-08
FR2847253A1 (fr) 2004-05-21
EP1611121B1 (fr) 2007-08-08
CO5700722A2 (es) 2006-11-30
NO20052887L (no) 2005-07-29
DE60315354T2 (de) 2008-05-08
WO2004046130A1 (fr) 2004-06-03
MXPA05005270A (es) 2005-07-25
AU2003296586A1 (en) 2004-06-15
NO20052887D0 (no) 2005-06-14
JP2006509748A (ja) 2006-03-23
KR20050083918A (ko) 2005-08-26
CA2518917A1 (fr) 2004-06-03
TW200418478A (en) 2004-10-01
DE60315354D1 (de) 2007-09-13
BR0316720A (pt) 2005-10-18
CN1741999A (zh) 2006-03-01

Similar Documents

Publication Publication Date Title
FR2847253B1 (fr) Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
MA27392A1 (fr) Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
FR16C0042I2 (fr) Derives de composes heterocycliques et medicaments
FR2836915B1 (fr) Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
NO20021599D0 (no) Nye farmasöytiske sammensetninger av anti-tuberkulose legemidler og fremgangsmåte for deres fremstilling
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
FR2911138B1 (fr) Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2761066B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CY2007033I1 (el) Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις
FR2911137B1 (fr) Nouveaux derives de 2,4-dianilinopyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
FR2807038B1 (fr) Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
FR2862647B1 (fr) Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
NO20043866L (no) Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
FR2919869B1 (fr) Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2840302B1 (fr) Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2850377B1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2854159B1 (fr) Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
FR2873690B1 (fr) Derives d'oxopiperidine, leur preparation et leur application en therapeutique
IL163959A (en) Derivatives of phenyl-sulfonylamino- benzoic acid and pharmaceutical compositions comprising them
IL166097A0 (en) Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole preparation process and intermediates of this process their use as medicaments and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160729